In preparation for effectiveness trials of candidate vaginal microbicides, scientists are debating trial design and implementation challenges, including choice of control arm(s), product-sharing across arms, and visit schedules. This study involved a survey of South African women participating in an expanded safety trial of the candidate microbicide Carraguard gel.The first 100 consenting women who attended the study clinics in Ga-Rankuwa and Gugulethu (total N = 200) were interviewed; all women had been using a study gel for at least 6 months at the time of the interview.The study found that many participants thought that including a condoms-only arm would result in increased product-sharing, male partner resistance to trial participation ...
Despite numerous scientific, ethical and methodological challenges, microbicides provide real potent...
The inconclusive results of past trials and recent findings of partial protection of Tenofovir 1% ge...
(See the editorial commentary by Padian, on pages 663–5.) Trials for the prevention of human immunod...
In preparation for effectiveness trials of candidate vaginal microbicides, scientists are debating t...
In preparation for effectiveness trials of candidate vaginal microbicides, scientists are debating t...
Low adherence in vaginal microbicide clinical trials for HIV prevention has impeded interpretation o...
BACKGROUND: With 2.5 million new HIV infections per year, effective preventive methods against HIV a...
The Microbicide Division of the Department of Medical Microbiology at MEDUNSA, South Africa, recentl...
Background: This research examined past microbicide effectiveness trials to better understand how ad...
Background With 2.5 million new HIV infections per year, effective preventive methods against HIV ar...
Introduction: Clinical trials of new vaginal products require careful communication with participant...
The Microbicide Division of the Department of Medical Microbiology at MEDUNSA, South Africa, recentl...
Objectives. We analyzed qualitative and quantitative data for 98 HIV-negative, low-risk women in Mal...
After two decades of microbicide clinical trials it remains uncertain if vaginally- delivered produc...
Introduction: Microbicides were conceptualized as a product that could give women increased agency o...
Despite numerous scientific, ethical and methodological challenges, microbicides provide real potent...
The inconclusive results of past trials and recent findings of partial protection of Tenofovir 1% ge...
(See the editorial commentary by Padian, on pages 663–5.) Trials for the prevention of human immunod...
In preparation for effectiveness trials of candidate vaginal microbicides, scientists are debating t...
In preparation for effectiveness trials of candidate vaginal microbicides, scientists are debating t...
Low adherence in vaginal microbicide clinical trials for HIV prevention has impeded interpretation o...
BACKGROUND: With 2.5 million new HIV infections per year, effective preventive methods against HIV a...
The Microbicide Division of the Department of Medical Microbiology at MEDUNSA, South Africa, recentl...
Background: This research examined past microbicide effectiveness trials to better understand how ad...
Background With 2.5 million new HIV infections per year, effective preventive methods against HIV ar...
Introduction: Clinical trials of new vaginal products require careful communication with participant...
The Microbicide Division of the Department of Medical Microbiology at MEDUNSA, South Africa, recentl...
Objectives. We analyzed qualitative and quantitative data for 98 HIV-negative, low-risk women in Mal...
After two decades of microbicide clinical trials it remains uncertain if vaginally- delivered produc...
Introduction: Microbicides were conceptualized as a product that could give women increased agency o...
Despite numerous scientific, ethical and methodological challenges, microbicides provide real potent...
The inconclusive results of past trials and recent findings of partial protection of Tenofovir 1% ge...
(See the editorial commentary by Padian, on pages 663–5.) Trials for the prevention of human immunod...